Divis Laboratories has reported results for third quarter ended December 31, 2012.
The company has registered a rise of 17.70% in its net profit at Rs 144.24 crore in Q3FY13 as compared to Rs 122.55 crore in the corresponding quarter previous year. The total income of the company has increased by 25.68% to Rs 556.68 crore for the quarter under review as compared to Rs 442.94 crore in the same quarter last year.
Divis Laboratories, together with its subsidiaries, engaged in the manufacture and sale of active pharma ingredients (APIs) and intermediates for the pharmaceutical industry in India and worldwide.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1933.10 |
| Dr. Reddys Labs. | 1210.85 |
| Cipla | 1418.40 |
| Lupin | 2442.10 |
| Zydus Lifesciences | 1142.75 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: